SCHEMBL6182656

SCHEMBL6182656

CC(=O)OS(=O)(=O)c1ccccc1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.53
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
MEN1 O00255 2/20 0.46
ESR1 P03372 2/20 0.46
KMT2A Q03164 2/20 0.46
ESR2 Q92731 2/20 0.46
GAA P10253 1/20 0.46
ATM Q13315 1/20 0.44
ALDH1A1 P00352 4/20 0.41
SLC1A3 P43003 1/20 0.40
SLC1A2 P43004 1/20 0.40
SLC1A1 P43005 1/20 0.40
ALOX12 P18054 1/20 0.39
HTT P42858 1/20 0.39
KAT6A Q92794 1/20 0.39
HSD11B1 P28845 1/20 0.37
HPGD P15428 2/20 0.37
HTR6 P50406 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15404492 0.86 POLB (0.54) POLBCYP1A2CYP2C9CYP2C19MEN1
SCHEMBL31148931 0.83 POLB (0.48) POLBCYP1A2CYP2C9CYP2C19MEN1
SCHEMBL9364060 0.83 POLB (0.48) POLBCYP1A2CYP2C9CYP2C19MEN1
SCHEMBL13268417 0.82 BCAT2 (0.42) POLBCYP1A2CYP2C19MEN1KMT2A
SCHEMBL9745499 0.81 CYP1A2 (0.48) POLBCYP1A2CYP2C9CYP2C19MEN1
SCHEMBL28193046 0.80 POLB (0.46) POLBCYP1A2CYP2C9CYP2C19MEN1
SCHEMBL14958316 0.80 CYP1A2 (0.50) POLBCYP1A2CYP2C9CYP2C19MEN1
SCHEMBL28157583 0.80 POLB (0.46) POLBCYP1A2CYP2C9CYP2C19MEN1
SCHEMBL28124089 0.79 HSD11B1 (0.42) POLBCYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL7470086 0.79 POLB (0.44) POLBCYP1A2CYP2C9CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6558736-B2 Vapor deposition in vacuum THE TRUSTEES OF PRINCETON UNIVERSITY 2003-05-06 US claimed
US-20020155230-A1 Low pressure vapor phase deposition of organic thin films FORREST STEPHEN R (US) 2002-10-24 US claimed
EP-1032722-A4 LOW PRESSURE VAPOR PHASE DEPOSITION OF ORGANIC THIN FILMS UNIV PRINCETON (US) 2001-09-12 EP claimed
US-20010002279-A1 Low pressure vapor phase deposition of organic thin films FORREST STEPHEN R (US) 2001-05-31 US claimed
EP-1032722-A1 LOW PRESSURE VAPOR PHASE DEPOSITION OF ORGANIC THIN FILMS THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2000-09-06 EP claimed
EP-0828867-A4 METHOD AND APPARATUS USING ORGANIC VAPOR PHASE DEPOSITION FOR THE GROWTH OF ORGANIC THIN FILMS WITH LARGE OPTICAL NON-LINEARITIES UNIV PRINCETON (US) 1999-10-27 EP claimed
WO-1999025894-A1 LOW PRESSURE VAPOR PHASE DEPOSITION OF ORGANIC THIN FILMS THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1999-05-27 WO claimed
EP-0828867-A2 METHOD AND APPARATUS USING ORGANIC VAPOR PHASE DEPOSITION FOR THE GROWTH OF ORGANIC THIN FILMS WITH LARGE OPTICAL NON-LINEARITIES THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1998-03-18 EP claimed
WO-1996037639-A2 METHOD AND APPARATUS USING ORGANIC VAPOR PHASE DEPOSITION FOR THE GROWTH OF ORGANIC THIN FILMS WITH LARGE OPTICAL NON-LINEARITIES THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1996-11-28 WO claimed
US-5554220-A Method and apparatus using organic vapor phase deposition for the growth of organic thin films with large optical non-linearities THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1996-09-10 US claimed
CN-102786373-A Synthetic method of diazomethane compound SHENZHEN IPI BIOLOG TECHNOLOGY CO LTD 2012-11-21 CN disclosed
EP-1519937-A1 PROCESS AND INTERMEDIATES FOR MAKING NON-NUCLEOSIDE HIV-1 REVERSE TRANSCRIPTASE INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2005-04-06 EP disclosed
US-6759533-B2 NOVEL INTERMEDIATES FOR THE SYNTHESIS OF CERTAIN NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2004-07-06 US disclosed
WO-2004002989-A1 PROCESS AND INTERMEDIATES FOR MAKING NON-NUCLEOSIDE HIV-1 REVERSE TRANSCRIPTASE INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2004-01-08 WO disclosed
US-20040002489-A1 Process and intermediates for making non-nucleoside HIV-1 reverse transcriptase inhibitors BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2004-01-01 US disclosed
WO-1996037639-A2 METHOD AND APPARATUS USING ORGANIC VAPOR PHASE DEPOSITION FOR THE GROWTH OF ORGANIC THIN FILMS WITH LARGE OPTICAL NON-LINEARITIES THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1996-11-28 WO disclosed
US-5554220-A Method and apparatus using organic vapor phase deposition for the growth of organic thin films with large optical non-linearities THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1996-09-10 US disclosed
EP-0023785-A2 Quinoxalinyloxyphenoxyalkane carboxylic acid derivatives, their preparation and their use as herbicides ICI AUSTRALIA LIMITED (AU) 1981-02-11 EP disclosed
EP-0013145-A2 Substituted anilinopyridines, processes for their preparation and intermediates for use therein, compositions and herbicidal use thereof ICI AUSTRALIA LIMITED (AU) 1980-07-09 EP disclosed
US-4116965-A STYRYL DYESTUFFS CONTAINING CERTAIN AMINO, CYANOPYRIDINE MOIETIES CIBA-GEIGY CORPORATION (US) 1978-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002489-A1 Process and intermediates for making non-nucleoside HIV-1 reverse transcriptase inhibitors REV1, POLR2E, POLR2H POLB 13/4885CYP1A2 1099/4885CYP2C9 1421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.